Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2016-03-24

FDA Approved: BETOPTIC S — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for Betoptic S (betaxolol hydrochloride) from Novartis, updating the drug's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BETOPTIC S (betaxolol hydrochloride)

Snippet

SUPPL AP for BETOPTIC S (BETAXOLOL HYDROCHLORIDE)